Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ICCM
stocks logo

ICCM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
901.00K
+2.97%
-0.040
-50%
2.15M
+196.97%
-0.040
-33.33%
2.95M
+462.48%
-0.030
-50%
Estimates Revision
The market is revising Downward the revenue expectations for IceCure Medical Ltd (ICCM) for FY2025, with the revenue forecasts being adjusted by -0.99% over the past three months. During the same period, the stock price has changed by -34.09%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.99%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-34.09%
In Past 3 Month
Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.679
sliders
Low
2.50
Averages
2.75
High
3.00
Current: 0.679
sliders
Low
2.50
Averages
2.75
High
3.00
H.C. Wainwright
Yi Chen
Buy
downgrade
$2
2025-08-15
Reason
H.C. Wainwright
Yi Chen
Price Target
$2
2025-08-15
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on IceCure Medical to $2 from $2.50 and keeps a Buy rating on the shares post the Q2 report. The firm's projected shares outstanding in 12 months increased meaningfully as a result of IceCure's recent rights offering.
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$2.5
2025-03-28
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$2.5
2025-03-28
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Icecure Medical Ltd (ICCM.O) is -6.17, compared to its 5-year average forward P/E of -5.36. For a more detailed relative valuation and DCF analysis to assess Icecure Medical Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.36
Current PE
-6.17
Overvalued PE
1.73
Undervalued PE
-12.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.81
Current PS
0.00
Overvalued PS
30.09
Undervalued PS
-0.46
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ICCM News & Events

Events Timeline

(ET)
2025-11-18
09:39:02
IceCure Medical's ProSense System Granted Regulatory Approval in Switzerland
select
2025-11-14 (ET)
2025-11-14
16:50:32
IceCure Medical Gets Nasdaq Noncompliance Notice
select
2025-11-10 (ET)
2025-11-10
08:31:53
Shay Levav Appointed COO of IceCure Medical
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-19Newsfilter
IceCure Announces Financial and Operational Performance for the Nine Months Ending September 30, 2025

  • FDA Marketing Authorization: IceCure Medical received FDA marketing authorization for its ProSense® cryoablation system, allowing treatment of low-risk breast cancer in women aged 70 and older, marking a significant advancement in minimally invasive cancer care.

  • Market Potential and Demand: The U.S. market for ProSense® is estimated to include around 200,000 patients, with increasing interest from medical professionals and anticipated growth in installations and procedure volumes following the FDA approval.

  • Financial Overview: For the nine months ending September 30, 2025, IceCure reported revenues of $2.1 million, a decrease from the previous year, alongside a net loss of $10.8 million, reflecting ongoing investments in research and development.

  • Global Expansion Plans: IceCure plans to expand ProSense® to 30 clinical sites in the U.S. and is pursuing regulatory approval in Japan, while also receiving regulatory clearance in Switzerland for broader indications.

[object Object]
Preview
9.5
11-19SeekingAlpha
IceCure Medical announces results for the nine-month period ending.

  • Revenue Performance: IceCure Medical reported revenue of $2.1 million for the nine months ending September 30, 2025, a decrease from $2.42 million in the same period in 2024.

  • Net Loss Comparison: The company's net loss for the nine months ended September 30, 2025, was $10.81 million, slightly improved from a loss of $10.84 million in the previous year.

  • Cash Position: As of September 30, 2025, IceCure Medical had approximately $10 million in cash and equivalents, an increase from $7.6 million at the end of 2024.

  • FDA Marketing Authorization: The press release mentions IceCure Medical's FDA marketing authorization for its ProSense Cryoablation device, indicating ongoing developments in their product offerings.

[object Object]
Preview
7.0
11-15PRnewswire
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

  • Nasdaq Compliance Notice: IceCure Medical Ltd. has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share, granting the company 180 days to regain compliance.

  • Regaining Compliance: The company can regain compliance if its share price exceeds $1.00 for at least ten consecutive business days within the grace period, which ends on May 11, 2026.

  • Potential Delisting: If compliance is not achieved after the initial 180 days, IceCure may be eligible for an additional compliance period, but failure to demonstrate compliance could lead to delisting.

  • Company's Focus: IceCure Medical specializes in minimally invasive cryoablation technology for tumor treatment, emphasizing the importance of maintaining its Nasdaq listing and exploring options to address the compliance issue.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Icecure Medical Ltd (ICCM) stock price today?

The current price of ICCM is 0.6789 USD — it has decreased -3.41 % in the last trading day.

arrow icon

What is Icecure Medical Ltd (ICCM)'s business?

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

arrow icon

What is the price predicton of ICCM Stock?

Wall Street analysts forecast ICCM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICCM is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Icecure Medical Ltd (ICCM)'s revenue for the last quarter?

Icecure Medical Ltd revenue for the last quarter amounts to 850.00K USD, increased 28.40 % YoY.

arrow icon

What is Icecure Medical Ltd (ICCM)'s earnings per share (EPS) for the last quarter?

Icecure Medical Ltd. EPS for the last quarter amounts to -0.06 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Icecure Medical Ltd (ICCM)'s fundamentals?

The market is revising Downward the revenue expectations for IceCure Medical Ltd (ICCM) for FY2025, with the revenue forecasts being adjusted by -0.99% over the past three months. During the same period, the stock price has changed by -34.09%.
arrow icon

How many employees does Icecure Medical Ltd (ICCM). have?

Icecure Medical Ltd (ICCM) has 64 emplpoyees as of December 05 2025.

arrow icon

What is Icecure Medical Ltd (ICCM) market cap?

Today ICCM has the market capitalization of 46.82M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free